MetaCap

Iovance Biotherapeutics Inc. (IOVA)

NASDAQ: IOVAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.90-0.41 (-5.61%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IOVA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.49
52-week range
2.08 – 15.37
Day range
6.77 – 7.40
Volume / Avg
13.73M / 14.91M
Beta
—

52-week range

$2.08$15.37

IOVA stock today

Shares of Iovance Biotherapeutics (IOVA) finished lower on Nov 20 at $6.90, a drop of 5.61% or $0.41 per share, versus the S&P 500's 3.70% decline. Shares are 55.1% below their 52-week high of $15.37, set on Oct 21, 2026 and 231.7% above the 52-week low of $2.08, in the middle of the past year's range. IOVA is up 152.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 208.0%.

Iovance Biotherapeutics has posted a net loss over the last twelve months (EPS of -$0.49), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Iovance Biotherapeutics

Company profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Headquarters
Philadelphia, PA
Employees
975

Financial highlights

Full financials

In fiscal 2025, Iovance Biotherapeutics generated $263.5 million in revenue, up 60.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Iovance Biotherapeutics reported a net loss of $391.0 million, compared with a loss of $372.2 million a year earlier. Gross margin was 34.3% (down from 43.2%) and operating margin -153.1%.

Iovance Biotherapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$263.50M$164.07M$1.19M——
Growth+60.60%+13698.99%———
Net income$-390.98M$-372.18M$-444.04M$-395.89M$-342.25M
EPS (diluted)$-1.09$-1.28$-1.89$-2.49$-2.23

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$14.50+110.14%

  • Strong buy 2
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.05 vs $-0.09
Surprise
+44.44%

IOVA news

All IOVA news

Iovance Biotherapeutics peers

Health Care sector
IOVA peer companies
CompanyPrice% ChgMarket capCompare
DNLIDenali Therapeutics Inc.18.45+1.37%$2.96Bvs IOVA
VCELVericel Corporation57.52-1.27%$2.94Bvs IOVA
ADMAADMA Biologics Inc13.17-1.27%$2.92Bvs IOVA
RLAYRelay Therapeutics Inc.16.12+1.32%$3.56Bvs IOVA
TARSTarsus Pharmaceuticals Inc.73.01-6.00%$3.60Bvs IOVA
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs IOVA
BEAMBeam Therapeutics Inc.20.90-0.19%$2.16Bvs IOVA
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs IOVA

Indexes, lists and sector

Iovance Biotherapeutics stock FAQ

What is Iovance Biotherapeutics's stock price today?

IOVA last traded at $6.90 as of Nov 20, 4:00 PM EST, down 5.61% on the day. Prices are delayed at least 15 minutes.

Does Iovance Biotherapeutics pay a dividend?

No. Iovance Biotherapeutics does not currently pay a regular cash dividend.

Who is Iovance Biotherapeutics's CEO?

Dr. Frederick G. Vogt Esq., J.D., Ph.D. is the chief executive officer of Iovance Biotherapeutics Inc., which has about 975 employees.

Has IOVA ever split its stock?

Yes. The most recent IOVA stock split was a 1-for-100 split on Sep 26, 2013.

What is the IOVA 52-week high?

The 52-week high for IOVA is $15.37 and the 52-week low is $2.08. The stock is currently 55.1% below its high.

Compare IOVA